SUPN
Indivior Pharmaceuticals Inc
SUPN's fundamentals are strong and it looks cheap: trading at 8.2x earnings, about a third of its usual 26x. Analysts expect strong earnings growth, though they disagree widely on how much.
SUPN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Under pressure | |
| Healthy |
SUPN's revenue, profitability and balance sheet are currently healthy, but its cash flow is under pressure.
SUPN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.4x | $29.20 | — |
| Current | 8.2x | $29.20 | — |
| Cheap | 18x | $63.68 | +118% |
| Fair | 26x | $91.92 | +215% |
| Expensive | 97x | $347 | +1088% |
Historical ranges are pointers, not guarantees.
SUPN's PE is in its cheap range at 8.2x. If earnings grow as analysts expect, today's price would be 7.4x next year's earnings.
SUPN Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for SUPN, but weaker profitability. However, they disagree widely on these estimates.
SUPN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.97 | +11% |
| Q3 2026 | $3.58 | +175% |
| Q2 2026 | $2.79 | +179% |
| Q1 2026 | $1.95 | +1293% |
| Q4 2025 | $1.64 | +681% |
| Q3 2025 | $1.30 | +829% |
| Q2 2025 | $1.00 | +$1.83 |
| Q1 2025 | $0.14 | -18% |
| Q4 2024 | $0.21 | +425% |
SUPN earned $3.58 per share over the past year, up 175% from the year before.
SUPN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $356M | +13% |
| Q2 2026 | $343M | +14% |
| Q1 2026 | $317M | +19% |
| Q4 2025 | $358M | +20% |
| Q3 2025 | $314M | +2.3% |
| Q2 2025 | $302M | +1% |
| Q1 2025 | $266M | -6.3% |
| Q4 2024 | $299M | +2% |
SUPN's revenue has grown year over year for six quarters in a row: $356M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 51% | +37 points |
| Q2 2026 | 47% | +23 points |
| Q1 2026 | 43% | +18 points |
| Q4 2025 | 23% | -9.5 points |
| Q3 2025 | 14% | +12 points |
| Q2 2025 | 24% | +63 points |
| Q1 2025 | 25% | -1.6 points |
| Q4 2024 | 32% | +11 points |
SUPN's operating margin was 51% last quarter, up 37 points from the same quarter a year ago, near the top of its range since 2021.
SUPN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $83M | +$142M |
| Q2 2026 | $222M | +57% |
| Q1 2026 | -$29M | -141% |
| Q4 2025 | -$245M | -$224M |
| Q3 2025 | -$59M | -$54M |
| Q2 2025 | $141M | +68% |
| Q1 2025 | $70M | +$110M |
| Q4 2024 | -$21M | +$278M |
SUPN has burned cash in most quarters: $31M over the past year, down 76% from the year before.
SUPN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -2M shares |
| 1 year | -5.4% | -7M shares |
| 3 years | -11% | -15.7M shares |
SUPN has 122M diluted shares, down 5.4% from a year ago, with $303M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $177M |
| Q1 2026 | $126M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $11M |
| Q4 2024 | $51M |
SUPN spent $303M buying back its own shares over the past year, about five times what it spent the year before.
SUPN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.7x | Net Cash |
| Q1 2025 | -0.5x | Net Cash |
| Q4 2024 | 0.5x | Very low |
SUPN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
SUPN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.4 | Neutral |
| Stochastic | 32.2 | Neutral |
SUPN's weekly RSI is 40 (neutral) and its Stochastic is 32 (neutral).
SUPN PE vs Healthcare Sector
| Metric | SUPN | Sector median | Relative |
|---|---|---|---|
| PE | 8.2x | 26x | 68% below |
| PE % | 1 | 29 | 28 pts below |
SUPN is trading at 8.2x earnings, a 68% discount to the Healthcare sector's median of 26x.
SUPN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.3 | 19% below |
| 20 week MA | $37.3 | 22% below |
| 50 week MA | $35.8 | 18% below |
| 100 week MA | $26.3 | 11% above |
| 200 week MA | $21.9 | 34% above |
SUPN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 34% above its 200-week average.
SUPN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.83 | $6.90 | +144% |
| 2021 | $6.90 | $17.8 | +157% |
| 2022 | $17.8 | $22.0 | +24% |
| 2023 | $22.0 | $15.3 | -31% |
| 2024 | $15.3 | $12.4 | -19% |
| 2025 | $12.4 | $36.2 | +192% |
| 2026 YTD | $36.2 | $29.2 | -19% |
SUPN has finished higher in four of the last six years, three of them by more than 50%. It's down 19% so far in 2026.